Ascentage Pharma (AAPG) said Friday that underwriters of its US initial public offering have partially exercised an over-allotment option to buy an additional 935,144 American depositary shares at the IPO price of $17.25 per ADS.
After the partial exercise of the over-allotment option, the total number of ADSs sold in the offering will rise to about 8.3 million ADSs and the gross proceeds will be about $142.5 million, the biopharmaceutical company said.
AAPG shares were over 2% higher ahead of Friday's opening bell.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.